Literature DB >> 27275481

Use of GeneXpert Mycobacterium tuberculosis/rifampicin for rapid detection of rifampicin resistant Mycobacterium tuberculosis strains of clinically suspected multi-drug resistance tuberculosis cases.

Kheira Guenaoui1, Noria Harir1, Aissa Ouardi1, Soumia Zeggai1, Feriel Sellam1, Farid Bekri1, Sakina Cherif Touil1.   

Abstract

BACKGROUND: Multi-drug resistance (MDR) TB is defined as tuberculosis (TB) disease caused by a strain of Mycobacterium tuberculosis (MTB) that was resistant to at least isoniazid and rifampicin (RIF). Emerging Multidrug-Resistant TB is one of the major concerns of health policy and rapid detection of M. tuberculosis and detection of RIF resistance in infected patients are essential for disease management. The aim of this study was to evaluate patterns of RIF resistance in cases of sputum positive pulmonary TB by using GeneXpert MTB/RIF and comparing between phenotypic and genotypic testing of RIF resistance in MTB strains of clinically suspected MDR-TB isolated cases in western Algeria.
METHODS: In this study 50 sputum positive cases of pulmonary TB who were potential MDR suspect were included. Their sputum samples were collected and subjected to sputum smear microscopy, culture and conventional MTB/RIF test followed by GeneXpert MTB/RIF assay.
RESULTS: Of total 50 cases included in this study, MTB was detected in all patients (100%) by GeneXpert MTB/RIF. However, RIF's resistance was detected in only 21 cases (42%) by GeneXpert MTB/RIF. All RIF resistant strains detected by GeneXpert MTB/RIF were phenotypically confirmed as MDR strains. 42.85% of cases were retreatment failure cases, retreatment cases smear positive at 4 months were 23.82%. While 19.05% of cases were retreatment cases smear positive at diagnosis, and 14.28% patient had history of contact with MDR-TB. Sensitivity, specificity, positive predictive value and negative predictive value of Xpert MTB/RIF to detect RIF resistance in comparison to conventional phenotypic drug susceptibility technique were found equal to the rates of 100%, 100%, 100% and 100%, respectively.
CONCLUSIONS: GeneXpert MTB/RIF assay is efficient and reliable technique for the rapid diagnostic of TB. It's simplicity, high sensitivity and specificity for RIF resistance detection make this technique a very attractive tool for diagnostic of MTB and RIF resistance in MDR cases.

Entities:  

Keywords:  GeneXpert MTB/RIF; Mycobacterium tuberculosis (MTB); multi-drug resistance (MDR); rifampicin resistance

Year:  2016        PMID: 27275481      PMCID: PMC4876276          DOI: 10.21037/atm.2016.05.09

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  23 in total

1.  Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?

Authors:  H T W Quy; N T N Lan; M W Borgdorff; J Grosset; P D Linh; L B Tung; D van Soolingen; M Raviglione; N V Cô; J Broekmans
Journal:  Int J Tuberc Lung Dis       Date:  2003-07       Impact factor: 2.373

2.  Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India.

Authors:  N Singla; R Singla; G Jain; L Habib; D Behera
Journal:  Int J Tuberc Lung Dis       Date:  2011-10       Impact factor: 2.373

Review 3.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

Authors:  A Faustini; A J Hall; C A Perucci
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

4.  DNA fingerprints of Mycobacterium tuberculosis do not change during the development of resistance to various antituberculous drugs.

Authors:  L Rigouts; F Portaels
Journal:  Tuber Lung Dis       Date:  1994-04

5.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

Review 6.  Rapid detection of resistance in Mycobacterium tuberculosis: a review discussing molecular approaches.

Authors:  D García de Viedma
Journal:  Clin Microbiol Infect       Date:  2003-05       Impact factor: 8.067

7.  Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes.

Authors:  T Yoshiyama; H Yanai; D Rhiengtong; P Palittapongarnpim; O Nampaisan; S Supawitkul; W Uthaivorawit; T Mori
Journal:  Int J Tuberc Lung Dis       Date:  2004-01       Impact factor: 2.373

8.  Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.

Authors:  A R Shah; S K Agarwal; K V Shah
Journal:  Int J Tuberc Lung Dis       Date:  2002-12       Impact factor: 2.373

9.  Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory.

Authors:  Marinus Barnard; Rob Warren; Nico Gey Van Pittius; Paul van Helden; Marlein Bosman; Elizabeth Streicher; Gerrit Coetzee; Richard O'Brien
Journal:  Am J Respir Crit Care Med       Date:  2012-10-18       Impact factor: 21.405

10.  Direct sequencing for rapid detection of multidrug resistant Mycobacterium tuberculosis strains in Morocco.

Authors:  Fathiah Zakham; Imane Chaoui; Amina Hadbae Echchaoui; Fouad Chetioui; My Driss Elmessaoudi; My Mustapha Ennaji; Mohammed Abid; Mohammed El Mzibri
Journal:  Infect Drug Resist       Date:  2013-11-28       Impact factor: 4.003

View more
  7 in total

1.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

Review 2.  Value of Xpert MTB/RIF Using Bronchoalveolar Lavage Fluid for the Diagnosis of Pulmonary Tuberculosis: a Systematic Review and Meta-analysis.

Authors:  Hong-Chao Liu; Yu-Lu Gao; Dan-Feng Li; Xi-Yi Zhao; Yuan-Qing Pan; Chang-Tai Zhu
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

3.  Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali.

Authors:  Bocar Baya; Chad J Achenbach; Bourahima Kone; Yacouba Toloba; Djeneba K Dabitao; Bassirou Diarra; Drissa Goita; Seydou Diabaté; Mamoudou Maiga; Dianguina Soumare; Khadidia Ouattara; Tenin Kanoute; Gaoussou Berthe; Youssouf M Kamia; Yeya Dit Sadio Sarro; Moumine Sanogo; Antieme C G Togo; Bindongo P P Dembele; Nadie Coulibaly; Amadou Kone; Maxwell Akanbi; Michael Belson; Sounkalo Dao; Susan Orsega; Sophia Siddiqui; Seydou Doumbia; Robert L Murphy; Souleymane Diallo
Journal:  Int J Infect Dis       Date:  2019-02-14       Impact factor: 3.623

4.  Comparing the impact of genotypic based diagnostic algorithm on time to treatment initiation and treatment outcomes among drug-resistant tuberculosis patients in Amhara region, Ethiopia.

Authors:  Getahun Molla Kassa; Mehari Woldemariam Merid; Atalay Goshu Muluneh; Haileab Fekadu Wolde
Journal:  PLoS One       Date:  2021-02-18       Impact factor: 3.240

5.  Comparison of GeneXpert MTB/RIF assay and LED-FM microscopy for the diagnosis of extra pulmonary tuberculosis in Khyber Pakhtunkhwa, Pakistan.

Authors:  Anwar Sheed Khan; Sajid Ali; Muhammad Tahir Khan; Sajjad Ahmed; Yasir Khattak; Muhammad Irfan; Wasim Sajjad
Journal:  Braz J Microbiol       Date:  2018-04-27       Impact factor: 2.476

Review 6.  Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis.

Authors:  Kaican Zong; Chen Luo; Hui Zhou; Yangzhi Jiang; Shiying Li
Journal:  BMC Microbiol       Date:  2019-08-05       Impact factor: 3.605

7.  Rifampicin resistance in Mycobacterium tuberculosis in Iran: a two-centre study.

Authors:  F Bahraminia; M Zangiabadian; M J Nasiri; M Fattahi; M Goudarzi; R Ranjbar; A A Imani Fooladi
Journal:  New Microbes New Infect       Date:  2021-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.